Monash Ivf Group Ltd · ASX:MVF
Monash Ivf — Shareholder Meeting (November 2015)
26 slides from Monash Ivf's shareholder meeting presentation, Nov 26, 2015
Slide 1: Monash IVF Group Annual General Meeting 2015
For personal use only Monash IVF Group Annual General Meeting 2015
Slide 2: Disclaimer
Disclaimer For personal use only The presentation has been prepared by Monash IVF Group Limited (ACN 169 302 309) (“MVF”) (including its subsidiaries, affiliates and associated companies) and provides general background information about MVF’s activities as at the date of this presentation. The info
Slide 3: Chairman's address
For personal use only Chairman’s address Richard Davis 3 Monash IVF Group | Annual General Meeting 2015
Slide 4: Key Achievements
For personal use only Organic growth Expanded domestic footprint Increased market share Successfully acquired additional womens health businesses Continued to increase doctor network Expanded low-intervention offering Key Achievements Continued focus on science and innovation 4 Monash
Slide 5: Financial Performance
Revenue and normalised earnings increased in FY2015 vs FY2014 However, financial performance was below For personal use only Prospectus forecasts ARS volumes in Key Markets were lower than expected (+1.1% vs +4.1%) resulting in lower revenue and associated earnings Delays to the opening of B
Slide 6: Monash IVF Group
For personal use only Monash IVF Group Annual General Meeting 2015
Slide 7: CEO Presentation
For personal use only CEO Presentation James Thiedeman 7 Monash IVF Group | Annual General Meeting 2015
Slide 8: Monash IVF Group is a market leader in womens health
Overview FY2015 Highlights Strategy H1FY2016 Outlook Overview of Monash IVF Group For personal use only Core Assisted Diagnostic and Ancillary Ultrasound Reproductive Services Services 22 clinics 2 specialised 17 clinics laboratories in Victoria 5 service centres and South Australia 15 Son
Slide 9: FY2015 Full Year Highlights
Overview FY2015 Highlights Strategy H1FY2016 Outlook FY2015 Full Year Highlights For personal use only $125.0m $23.3m Revenue Normalised NPAT FY14 $114.0m FY14 $22.6m FY15 prospectus $130.3m FY15 prospectus $26.0m $41.3m $37.9m Normalised EBITDA Normalised EBIT FY14 $39.7m FY14 $36.8m FY15 prospectu
Slide 10: Revenue Analysis
Overview FY2015 Highlights Strategy H1FY2016 Outlook Revenue Analysis For personal use only Revenue $m Actual FY2015 vs Prospectus 130.3 (5.2) (3.6) 0.8 125.0 3.0 0.1 (0.4) FY15 prospectus Market growth Market share Pricing and mix Other income Acquisitions International FY15 Actual (ARS) (ARS) (ARS
Slide 11: Expanding Domestic Footprint
Overview FY2015 Highlights Strategy H1FY2016 Outlook Expanding Domestic Footprint For personal use only SUFW network (11 practices across Sydney, acquired June 2015) integration commenced Monash IVF Bondi Junction, Sydney (acquired December 2014) Acquisitions and New Wagga Wagga (regional NSW)
Slide 12: International – KL Fertility
Overview FY2015 Highlights Strategy H1FY2016 Outlook International – KL Fertility For personal use only Continued growth in volumes achieved by new Fertility Specialists Margin compression as these specialists gain traction Further international opportunities are being reviewed FY2015 FY2014 %
Slide 13: Science and Innovation
Overview FY2015 Highlights Strategy H1FY2016 Outlook Science and Innovation For personal use only The Group continues to invest in research and innovation across the clinic network including through the Monash IVF Research and Education Foundation (MREF) • During FY2015, 15 projects were funded ai
Slide 14: Our Brands and Marketing
Overview FY2015 Highlights Strategy H1FY2016 Outlook Our Brands and Marketing For personal use only 14 Monash IVF Group | Annual General Meeting 2015
Slide 15: Strategy FY2016 and Beyond
Overview FY2015 Highlights Strategy H1FY2016 Outlook Strategy FY2016 and Beyond For personal use only Our strategy remains consistent and focused; to profitably grow our business through leveraging our scientific capabilities across the clinic network Science, Continue to develop industry leading
Slide 16: FY2016 Trading Update
Overview FY2015 Highlights Strategy H1FY2016 Outlook FY2016 Trading Update For personal use only We are experiencing a reversion to long term market trend growth rates in the 4 months to Oct 15 Total Key Market1 Patient Treatments increased by 5.6% in the 4 months to Oct 15 vs pcp (declined by -0.
Slide 17: FY2016 Trading Update (continued)
For personal use only Overview FY2015 Highlights Strategy H1FY2016 Outlook FY2016 Trading Update (continued) Acquisitions update Monash IVF (Bondi Junction Sydney) (acquired December 2014) rebranding to Monash IVF complete and integrated into our existing NSW footprint SUFW network (11 practices
Slide 18: H1FY2016 Outlook
Overview FY2015 Highlights Strategy H1FY2016 Outlook H1FY2016 Outlook For personal use only As a result of the underlying growth in the overall market, improvement in market share and the impact of the acquisitions into the Monash IVF Group in FY2015, and subject to trading in the remaining months,
Slide 19: Summary
Monash IVF delivered a solid performance in an ARS market that grew slower than expected in Australia in FY15 For personal use only Fundamental drivers for the industry remain unchanged, despite lower overall market growth in FY15 In first quarter of FY16, we are seeing a return to more normal
Slide 20: Monash IVF Group
For personal use only Monash IVF Group Annual General Meeting 2015
Slide 21: Business of the AGM
For personal use only Business of the AGM 21 Monash IVF Group | Annual General Meeting 2015
Slide 22: Resolution One
For personal use only To receive and consider the Financial Report, Director’s Report and Auditor’s Report for the year ended 30 June 2015 . There is no requirement for a formal resolution on this item. Shareholders can ask questions of the Board or comment on the management of the company. Sharehol
Slide 23: Resolution Two
For personal use only That the Remuneration Report, which forms part of the Director’s Report for the year ended 30 June 2015, be adopted. Proxy voting: Votes in favour of the resolution – 106,860,205 (88.6%) Votes against the resolution – 13,424,781 (11.1%) Open votes – 322,198 (0.3%) Abstentions –
Slide 24: Resolution Three A
For personal use only That Mr Josef Czyzewski, who retires in accordance with the Company’s Constitution, be re-elected as a director of the Company. Proxy voting: Votes in favour of the resolution – 121,292,557 (99.5%) Votes against the resolution – 331,805 (0.3%) Resolution Three A Open votes – 30
Slide 25: Resolution Three B
For personal use only That Ms Christina Boyce, who retires in accordance with the Company’s Constitution, be re-elected as a director of the Company. Proxy voting: Votes in favour of the resolution – 121,304,901 (99.5%) Votes against the resolution – 315,721 (0.3%) Resolution Three B Open votes – 31
Slide 26: Thank you for attending
For personal use only Thank you for attending 26 Monash IVF Group | Annual General Meeting 2015
Monash IVF Group — Shareholder Meeting (November 2015) on 6ix